Financial Performance - Revenue for 2023 reached 39.11 billion yuan, a 7.19% increase compared to 2022[12] - Net profit attributable to shareholders of the listed company in 2023 was 4.09 billion yuan, a 36.41% increase year-on-year[12] - Basic earnings per share (EPS) for 2023 was 2.29 yuan, a 20.53% increase compared to 2022[12] - Total assets at the end of 2023 were 53.78 billion yuan, a 0.87% increase compared to the end of 2022[12] - Net cash flow from operating activities in 2023 was 3.50 billion yuan, a 9.14% increase year-on-year[12] - Gross profit margin in Q4 2023 was 23.77%, an increase of 2.76 percentage points compared to Q4 2022[17] - Non-recurring gains and losses in 2023 totaled 330.18 million yuan, compared to a loss of 230.90 million yuan in 2022[19] - Revenue in 2023 reached 39.111 billion yuan, a year-on-year increase of 7.19%, with industrial income growing by 7.58%[40] - Net profit attributable to shareholders in 2023 was 4.094 billion yuan, a year-on-year increase of 36.41%[40] - The company's weighted average return on equity (ROE) in 2023 was 10.51%, an increase of 2.64 percentage points year-on-year[40] - The company's trading financial assets decreased significantly by 93.82% to 149 million yuan at the end of 2023[40] - Total operating revenue for the period was RMB 39,111,292,156, a year-on-year increase of 7.19%[64] - Industrial sales revenue increased by 7.58% to RMB 13,740,557,061.12, accounting for 35.13% of total revenue[64] - Commercial sales revenue grew by 6.98% to RMB 25,295,257,277.35, representing 64.68% of total revenue[64] - Overseas revenue surged by 51.25% to RMB 634,184,770.26, accounting for 1.62% of total revenue[65] - Gross profit margin for industrial products (self-made) increased by 0.77% to 64.24%[66] - Direct material costs for industrial sales rose by 6.66% to RMB 4,225,537,847, accounting for 14.70% of total operating costs[69] - Procurement costs for commercial sales increased by 7.20% to RMB 23,769,165,686.54, representing 82.69% of total operating costs[69] - Technical service revenue grew significantly by 61.93% to RMB 10,743,024.62[64] - Sales expenses increased by 19.84% year-over-year to 4,992,157,591.11 RMB due to growth in sales scale[75] - Management expenses increased by 26.95% year-over-year to 1,058,503,523.90 RMB, primarily due to a 243 million RMB increase in employee compensation[75] - Operating cash flow increased by 9.14% to RMB 3.50 billion in 2023, driven by a RMB 2.42 billion increase in cash received from sales of goods and services[80][81] - Investment cash flow turned positive at RMB 518.58 million in 2023, a significant improvement from a negative RMB 6.32 billion in 2022, mainly due to reduced investment payments[80][82] - Financing cash flow decreased by 6.76% to negative RMB 2.92 billion in 2023, primarily due to reduced borrowing and increased dividend payments[81][82] - Net cash and cash equivalents increased by 118.98% to RMB 1.11 billion in 2023, reversing a negative RMB 5.82 billion in 2022[81] - Investment income was RMB 779,010,728.82, accounting for 16.17% of total profit, mainly from Shanghai Pharmaceutical investment income and the disposal of subsidiary Wanlong Xingye Commerce (Shenzhen) Co., Ltd.[83] - Fair value change gains and losses amounted to RMB 123,566,330.46, accounting for 2.56% of total profit, primarily due to changes in the net value of securities and funds held by the company[83] - Monetary funds increased by 1.95% to RMB 14,218,343,076.67, accounting for 26.44% of total assets[85] - Accounts receivable increased by 1.48% to RMB 9,966,170,447.21, accounting for 18.53% of total assets, mainly due to an increase in receivables from provincial pharmaceutical companies[85] - Inventory decreased by 3.01% to RMB 6,442,194,823.67, accounting for 11.98% of total assets, reflecting improved inventory management efficiency[85] - Construction in progress increased by 0.62% to RMB 529,708,553.58, accounting for 0.98% of total assets, due to increased investment in ongoing projects[85] - Other current assets increased by 4.43% to RMB 2,862,076,217.20, accounting for 5.32% of total assets, mainly due to an increase in fixed deposits[85] - The company's total investment in the reporting period was RMB 4,454,516,459.62, a decrease of 66.15% compared to the same period last year[88] - Restricted assets at the end of the reporting period amounted to RMB 12,215,524,167.74, including RMB 48,618,045.43 in monetary funds for guarantees and RMB 11,536,646,559.56 in long-term equity investments restricted from transfer[87] - The company invested RMB 273.55 million in the construction of the Yunnan Baiyao Shanghai International Center, with a cumulative investment of RMB 567.43 million, achieving 50.89% progress[90] - The Yunnan Baiyao R&D Platform - Kunming Center project received an investment of RMB 66.90 million, with a cumulative investment of RMB 87.20 million, achieving 11.04% progress[90] - The company's investment in Jacobson Pharmaceutical (HK.02633) resulted in a fair value loss of RMB 48.37 million, with a year-end book value of RMB 115.99 million[91] - The investment in China Antibody (HK.03681) yielded a fair value gain of RMB 9.54 million, with a year-end book value of RMB 72.55 million[91] - The company received 50.90 million shares of Jianbei Miaomiao (HK.02161) as a special dividend from Jacobson Pharmaceutical, valued at RMB 54.43 million[92] - The investment in Xiaomi Group (HK.01810) had a year-end book value of RMB 1.22 billion, with a fair value gain of RMB 157.68 million during the reporting period[92] - The total investment in securities amounted to RMB 4.74 billion, with a year-end book value of RMB 2.52 billion and a total realized gain of RMB 188.65 million[92] - Yunnan Pharmaceutical Co., Ltd., a subsidiary, reported revenue of RMB 24.49 billion and a net profit of RMB 412.99 million[97] - Yunnan Baiyao Group Health Products Co., Ltd., another subsidiary, achieved revenue of RMB 6.42 billion and a net profit of RMB 2.02 billion[97] - Total compensation for key executives in 2023 amounted to 3,909.45 million RMB[147] Dividend and Share Capital - The company's total share capital at the end of 2023 was 1,796,862,549 shares, with 12,599,946 shares repurchased, resulting in a base of 1,784,262,603 shares for dividend distribution[3] - The proposed cash dividend is RMB 20.77 per 10 shares (tax included), with no bonus shares or capital reserve transfers[3] - Total share capital as of the last trading day before disclosure was 1.80 billion shares[14] - Yunnan Baiyao has accumulated cash dividends exceeding 20.7 billion yuan by the end of 2022[24] - Cumulative cash dividends exceed RMB 20.7 billion since listing[110] - Cash dividend distribution for 2022: RMB 2,712,079,156.56, with RMB 15.20 per 10 shares[161] - Cash dividend distribution for 2023: RMB 3,705,913,426.43, with RMB 20.77 per 10 shares[163] - Total shares for dividend distribution in 2023: 1,784,262,603 shares[163] - Stock option incentive plan adjustments in 2022: 15,760,108 options adjusted from 11,257,220, with exercise price reduced from RMB 74.05 to RMB 51.75[165] - Number of stock options canceled in 2022: 947,054 due to unmet exercise conditions[165] - Total stock options remaining after cancellations: 6,772,080 for initial grants and 840,000 for reserved grants[165] - Number of employees eligible for stock options after adjustments: 653, down from 671[165] - The company canceled 6,252,954 stock options exercised and 947,054 unexercised stock options from the first exercisable period of the 2020 stock option incentive plan[166] - Due to unmet performance targets in 2021, the company canceled 7,086,240 stock options from the second exercisable period and 840,000 stock options from the first exercisable period of the reserved portion of the 2020 stock option incentive plan[166] - The company canceled 314,160 stock options from 18 former employees who were no longer eligible for the 2020 stock option incentive plan[166] - In total, the company canceled 9,187,454 stock options related to the 2020 stock option incentive plan as of September 7, 2022[166] - The company canceled 6,772,080 stock options from the third exercisable period and 840,000 stock options from the second exercisable period of the reserved portion of the 2020 stock option incentive plan due to unmet 2022 performance targets[167] - The company completed the cancellation of 7,612,080 stock options on September 7, 2023, effectively terminating the 2020 stock option incentive plan[167] - The 2021 employee stock ownership plan was terminated early after all 23,379,996 shares were sold by May 26, 2023[170] - The employee stock ownership plan covered 1,312 employees, including directors, supervisors, and senior management, holding 23,379,996 shares, representing 1.30% of the company's total share capital[168] - Senior executives, including the CEO and other key officers, held no shares at the end of the reporting period, compared to initial holdings ranging from 21,690 to 520,570 shares[169][170] Business Operations and Market Share - Yunnan Baiyao's core product, Yunnan Baiyao Powder, holds a 14.5% market share in the retail market for musculoskeletal system trauma-related systemic Chinese patent medicines[25] - Yunnan Baiyao Aerosol holds a 91.0% market share in the retail market for musculoskeletal system joint and muscle pain-related topical Chinese patent medicine aerosols[25] - Yunnan Baiyao Band-Aid holds a 66.5% market share in the retail market for external hemostatic (medicated) band-aids[25] - Yunnan Baiyao Toothpaste captured a 24.60% domestic market share in 2023, maintaining its leading position in the industry[25] - The company has 567 drug approval numbers and 316 varieties, including 222 Chinese patent medicine varieties, of which 43 are exclusive varieties[25] - The company is focusing on the secondary development of traditional Chinese medicine products, including Gongxuening Capsule and Qixuekang Oral Liquid[25] - Yunnan Baiyao is developing three new Class 1.1 Chinese medicine drugs, including Quansanqi Tablet, Fuqi Guben Ointment, and Xianghuo Spray[25] - Yunnan Baiyao's pharmaceutical business focuses on hemostasis, analgesia, and anti-inflammatory products, including Yunnan Baiyao aerosol, Yunnan Baiyao plaster, and Yunnan Baiyao band-aids, while also expanding into new growth areas such as cardiovascular and children's health products[26] - The health products business, centered on toothpaste, explores new consumer scenarios in oral care and anti-hair loss products, leveraging brand infrastructure to empower marketing[26] - The traditional Chinese medicine (TCM) resources business ensures high-quality, low-cost supply of TCM raw materials while developing B2B and B2C products, including Panax notoginseng series and health foods, and promotes digitalization in TCM resource cultivation[26] - Yunnan Baiyao is transitioning from a traditional manufacturing enterprise to a global leader in comprehensive healthcare solutions, driven by innovation in biotech, AI, and big data, with a focus on platformization and digitalization[27] - The company is expanding its regional presence with strategic hubs in Kunming, Beijing, and Shanghai, focusing on TCM research, innovation incubation, and international collaboration[28] - Yunnan Baiyao is shifting from traditional internal growth to a "dual-drive" model, combining internal development with mergers, acquisitions, and patent licensing to introduce innovative products globally[29] - The company is adopting a "dual-channel" talent strategy, combining internal training with external recruitment to build a high-quality talent pool for strategic investment, R&D, and user operations[30] - Yunnan Baiyao is transforming into a smart enterprise with a digital foundation, leveraging cloud computing, big data, AI, and IoT to enhance customer experience and decision-making[31] - The company's brand value continues to grow, with Yunnan Baiyao ranking 35th in Interbrand's 2023 China Best Brands and 1st in the pharmaceutical industry[33] - The pharmaceutical business group achieved revenue of 6.481 billion yuan, a year-on-year increase of 8.16%, with a gross profit margin of 70.6%[41] - Yunnan Baiyao aerosol contributed over 1.7 billion yuan in sales revenue, a year-on-year increase of 15.27%[41] - Yunnan Baiyao plaster sales exceeded 900 million yuan, and Yunnan Baiyao capsule sales exceeded 600 million yuan[41] - The company's OTC channels cover over 400,000 stores nationwide, with a focus on 5,000 leading chain pharmacies[38] - Yunnan Baiyao toothpaste maintained the top sales share in all channels, including hypermarkets, supermarkets, and convenience stores[38] - The health products business group achieved revenue of 6.422 billion yuan, a year-on-year increase of 6.50%, with Yunnan Baiyao toothpaste maintaining a 24.60% domestic market share[44] - The health products business group's Yangyuanqing anti-hair loss product achieved a breakthrough growth with sales exceeding 300 million yuan, a year-on-year increase of 36%[44] - The health products business group's Yunnan Baiyao Tmall flagship store achieved a breakthrough with single-store sales exceeding 100 million yuan during the 2023 "Double 11" period[44] - The traditional Chinese medicine resources business group achieved external revenue of 1.71 billion yuan, a year-on-year increase of approximately 22%, with Sanqi (Panax notoginseng) external sales revenue increasing by 81%[46] - The traditional Chinese medicine resources business group effectively controlled the increase in raw material costs, with the rise in the company's raw material prices significantly lower than the industry average[46] - The pharmaceutical business group plans to deepen academic research and collaborate with various institutions to develop existing products and explore potential products for future growth[43] - The health products business group aims to become an integrated oral health, scalp care, and body care solution provider, focusing on technological innovation and new channel growth[45] - The traditional Chinese medicine resources business group will focus on building a sustainable supply chain system for Yunnan's authentic medicinal materials and developing a brand medicinal materials ecosystem[47] - The traditional Chinese medicine resources business group will enhance its natural plant extraction business, with eucalyptus oil market share further increasing and capsaicin sales quadrupling[46] - Provincial Pharmaceutical Company achieved main business revenue of 24.49 billion yuan, a year-on-year increase of 5.63%[48] - Order fulfillment rate increased by 7.4%, order response speed improved by 22%, and delivery speed increased by 19%[48] - The company launched "Same Day Delivery, Next Day Delivery, Two-Day Delivery, and Scheduled Delivery" services to enhance service efficiency[48] - The company established new business units including Health Supplements, Skincare, Medical Devices, and Tianyi Tea Products to explore new growth opportunities[49] - The company is focusing on developing functional skincare products based on natural herbal ingredients[49] - The company is committed to upgrading the tea industry and exploring tea-derived products[50] - The company increased R&D investment and established a scientific and efficient R&D management system[51] - The company is leveraging AI-assisted drug design and focusing on innovative drug development[51] - The company completed 1,791 patient enrollments for the clinical observation study of Gongxuening Capsule for uterine bleeding, with results expected by the end of 2024[53] - The clinical study for improving cardiovascular health using Qixue Kang Oral Liquid completed 70% patient enrollment, with preliminary results showing potential benefits for vascular health[54] - The clinical II study of the innovative traditional Chinese medicine Quansanqi Tablet has enrolled 237 cases, with 211 cases completed, and the clinical summary report is expected in 2025[56][57] - The clinical II study of Fuqi Guben Ointment has been completed, and the clinical III study design and preparation are underway[56][57] - Two classic traditional Chinese medicine formulations (PZ-018, PZ-019) have completed pilot-scale process and quality standard research, with plans to submit a new drug application in 2024[56][57] - The INR101 project for prostate cancer diagnosis has completed pilot-scale production and received clinical trial acceptance notice from the National Medical Products Administration in February 2024[57][58] - The INR102 project for prostate cancer treatment has completed efficacy evaluation in model animals and initiated pharmaceutical research[57][58] - The company launched its first digital

关于云南白药集团股份有限公司 非经营性资金占用及 其他关联资金往来情况 汇总表的专项审核报告 众环专字(2024)1600030号 ll 量 页 次 专项审核报告 汇总表 非经营性资金占用及其他关联资金往来的情况汇总表 1-2 U y 1-2 LI 宙介环스汁而車名所(些碟並通合伙) t 汉 市中北路 166 号长江产业大厦 17-18 楼 关于云南自药集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2024)1600030 号 云南白药集团股份有限公司全体股东: 表应当与已审的财务报表一并阅读。 本审核报告仅供云南白药 2023年度年报披露之目的使用,不得用作任何其他目的。 我们接受委托,在审计了云南白药集团股份有限公司（以下简称"云南白药"）2023年 12 月 31 日合并及公司的资产负债表,2023年度合并及公司的利润表、合并及公司的现金流量表和 合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2023 年度非经 营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇总表")进行了专项审核。按 照中国证券监督管理委员会印发的《上市公 ...

关于本报告 董事会 ESG 声明 1 目录 专题 | 党建引领 | 01 | 稳健经营 02 | | --- | --- | | | 护航高质量发展 | | 021 | 033 | | --- | --- | | 025 | 039 | | 029 | 047 | 守正创新 激发新中药活力 ESG 管理 产品质量 合规管理 研发创新 商业道德 客户服务 03 扎根山野 守护和谐生态圈 | | | | | | | 109 | 关键绩效表 | | --- | --- | | 113 | GRI 索引 | 04 聚焦人才 携手员工成长 | 079 | 保障员工权益 | | --- | --- | | 083 | 赋能人才发展 | | 089 | 增进员工福祉 | | 095 | 守护健康安全 | 053 供应链管理 071 资源利用 001 005 015 002 003 关于本报告 关于我们 董事会 ESG 声明 董事长致辞 公司概况 2023 年亮点绩效 白药印象 067 环境管理 05 责任践行 增进民生幸福感 乡村振兴 101 105 107 社区关怀 社会公益 116 法律法规与内部制度表 120 读者反 ...

云南白药集团股份有限公司 内部控制审计报告 内部控制审计报告 众环审字(2024)1600082号 ring and the count a e e and contr U 一、云南白药对内部控制的责任 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 众环审字(2024)1600082 号 云南白药集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了云 南自药集团股份有限公司（以下简称"云南自药"）2023 年 12 月 31 日的财务报告内部控制的 有效性。 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制,并评价其有效性是云南白药董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的 ...

云南白药集团股份有限公司 审计报告 众环审字(2024)1600081号 ■ 型 | | 页次 | | --- | --- | | 审计报告 | 1-4 | | 财务报表 | | | 合并资产负债表 | 1-2 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | ર-6 | | 资产负债表 | 7-8 | | 利润表 | ರ | | 现金流量表 | 10 | | 股东权益变动表 | 11-12 | | 财务报表附注 | 13-117 | u u al 市众环会计师事务所(特殊普通合伙 No 166 Zhonghei Road, Wuhan 43 审计报告 众环审字(2024)1600081 号 云南白药集团股份有限公司全体股东: 一、审计意见 我们审计了云南白药集团股份有限公司(以下简称"云南白药")财务报表,包括 2023年 12 月 31 日的合并及公司资产负债表,2023年度的合并及公司利润表、合并及公司现金流量表、合 并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了云 南自药 2023年 ...

云南白药集团股份有限公司 2023 年度独立董事述职报告 各位股东： 本人作为云南白药集团股份有限公司（以下简称"公司"）独立董事，2023 年严格遵照《 公司法》 证券法》 上市公司治理准则》 上市公司独立董事 管理办法》 关于上市公司独立董事制度改革的意见》等法律法规和规范性文 件，以及本公司《 公司章程》 独立董事年报工作制度》等有关规定要求，谨 遵诚信、忠实、勤勉的原则，恪守独立董事履职规范，谨慎、独立、客观地行 使独立董事权利及义务，充分发挥独立董事作用，切实维护公司及全体股东尤 其是中小股东的合法权益。现就2023年度履职情况汇报如下： 一、会议出席情况 2023年，公司第十届董事会共召开7次会议，本人严格按照相关规范要求 出席全部董事会会议7次；2023年，公司共召开2次股东大会，本人列席2次会 议。具体参会情况如下表所示： 本人认为，报告期内，公司历次董事会、股东大会的召集、召开内容和程 序均符合法律法规、规范性文件以及公司章程之规定。在每次会议召开前，本 P A G E 1 5 本报告期应 参加董事会 次数 现场出 席次数 以通讯 方式参 加次数 委托出席 次数 缺席 次数 是否连续 两次未 ...

云南白药集团股份有限公司 董事会议事规则 （经第十届董事会 2024 年第三次会议审议修订稿） 第一章 总 则 第一条 为规范云南白药集团股份有限公司（以下简称"公司" 或"本公司"）董事会的行为，确保董事会高效运作和科学决策，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》和《云南白药集团股份有限公司公司章程》（以下简 称《公司章程》）的规定，制定本规则。 第二条 董事会是股东大会的执行机构，在股东大会闭会期间负 责公司重大经营决策，对股东大会负责。 第三条 董事会秘书负责董事会会议的组织和准备工作，包括安 排会议日程、准备会议文件、组织会议召开、负责会议记录、起草会 议决议、纪要等。 第二章 董事会的组成与职权 第四条 董事会由十一名董事组成，设董事长一人，可以设联席 董事长一人、副董事长一人。 第五条 公司董事会设立审计委员会，并根据需要设立战略委员 会、提名委员会、薪酬与考核委员会等相关专门委员会。专门委员会 对董事会负责，依照《公司章程》和董事会授权履行职责，提案应当 提交董事会审议决定。专门委员会成员全部由董事组成，其中审计委 员会、提名委员会、薪酬与考核委员会中独 ...

公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务 报告及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由 于内部控制存在的固有局限性，故仅能为实现上述目标提供合理保证。此 外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序 遵循的程度降低，根据内部控制评价结果推测未来内部控制的有效性具有 一定的风险。 二、内部控制评价结论 云南白药集团股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控 制监管要求（以下简称"企业内部控制规范体系"），结合云南白药集团 股份有限公司（以下简称"公司"）内部控制制度和评价办法，在内部控 制日常监督和专项监督的基础上，我们对公司 2023 年 12 月 31 日（内部 控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制， 评价其有效性，并如实披露内部控制评价报告是公司董事会的责任。监事 会对董事会建立和实施内部控制进行监督。经理层负责组织领导企业内部 控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证 本 ...

云南白药集团股份有限公司 2023 年度独立董事述职报告 各位股东： 本人作为云南白药集团股份有限公司（以下简称"公司"）独立董事，2023 年严格遵照《 公司法》 证券法》 上市公司治理准则》 上市公司独立董事 管理办法》 关于上市公司独立董事制度改革的意见》等法律法规和规范性文 件，以及本公司《 公司章程》 独立董事年报工作制度》等有关规定要求，谨 遵诚信、忠实、勤勉的原则，恪守独立董事履职规范，谨慎、独立、客观地行 使独立董事权利及义务，充分发挥独立董事作用，切实维护公司及全体股东尤 其是中小股东的合法权益。现就2023年度履职情况汇报如下： 一、会议出席情况 2023年，公司第十届董事会共召开7次会议，本人严格按照相关规范要求 出席全部董事会会议7次；2023年，公司共召开2次股东大会，本人列席2次会 议，未在现场工作。具体参会情况如下表所示： 本人认为，报告期内，公司历次董事会、股东大会的召集、召开内容和程 序均符合法律法规、规范性文件以及公司章程之规定。在每次会议召开前，本 P A G E 1 5 本报告期应参 加董事会次数 现场出席 次数 以通讯 方式参 加次数 委托出席 次数 缺席 次数 是否 ...

云南白药集团股份有限公司 第十届监事会 2024 年第一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"）第十届监事会 2024 年 第一次会议（以下简称"会议"）于 2024 年 3 月 28 日在公司"白药空间"二 楼会议室以现场会议的方式召开，本次会议通知于 2024 年 3 月 18 日以书面、 邮件或传真方式发出，应出席监事 4 名，现场出席 4 人，会议有效行使表决 权票数 4 票。会议的召集、召开程序符合《中华人民共和国公司法》《公司章 程》的相关规定，会议合法有效。会议由监事会主席游光辉主持，与会监事充 分讨论，审议通过了以下议案并形成如下决议： 一、审议通过《2023 年度监事会工作报告》 股票代码：000538 股票简称：云南白药 公告编号：2024-16 具体内容详见公司同日在巨潮资讯网的挂网公告《2023 年度监事会工作 报告》（网址：http://www.cninfo.com.cn）。 本项议案尚需提交公司 2023 年度股东大会审议。 表决结果：同意 4 票，反对 0 票，弃 ...